ENTR Trademark

Trademark Overview


On Tuesday, December 20, 2022, a trademark application was filed for ENTR with the United States Patent and Trademark Office. The USPTO has given the ENTR trademark a serial number of 79362246. The federal status of this trademark filing is REQUEST FOR EXTENSION OF TIME TO FILE OPPOSITION as of Tuesday, June 25, 2024. This trademark is owned by STEMON Inc.. The ENTR trademark is filed in the Pharmaceutical Products category with the following description:

Exosomes for medical use; biological preparations for the treatment of Inflammatory diseases, Regenerative disease, Infectious disease, Immune-related diseases, Respiratory disease, Ocular disease, Cancer, Metastatic disease, Cardiovascular disease, Neurodegenerative disease, and Metabolic disease for human or veterinary purposes; living cells for medical purposes; Pharmaceutical preparations for treatment of Inflammatory diseases, Regenerative disease, Infectious disease, Immune-related diseases, Respiratory disease, Ocular disease, Cancer, Metastatic disease, Cardiovascular disease, Neurodegenerative disease, and Metabolic disease; stem cells for medical purposes; Medicated creams for treating dermatological conditions; Medicated skincare preparations, namely, creams, lotions, gels, toners, cleaners and peels; Colostral antibodies for medical purposes; Medicated dermatological preparations and substances for skin renewal
entr

General Information


Serial Number79362246
Word MarkENTR
Filing DateTuesday, December 20, 2022
Status802 - REQUEST FOR EXTENSION OF TIME TO FILE OPPOSITION
Status DateTuesday, June 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, May 28, 2024

Trademark Statements


Goods and ServicesExosomes for medical use; biological preparations for the treatment of Inflammatory diseases, Regenerative disease, Infectious disease, Immune-related diseases, Respiratory disease, Ocular disease, Cancer, Metastatic disease, Cardiovascular disease, Neurodegenerative disease, and Metabolic disease for human or veterinary purposes; living cells for medical purposes; Pharmaceutical preparations for treatment of Inflammatory diseases, Regenerative disease, Infectious disease, Immune-related diseases, Respiratory disease, Ocular disease, Cancer, Metastatic disease, Cardiovascular disease, Neurodegenerative disease, and Metabolic disease; stem cells for medical purposes; Medicated creams for treating dermatological conditions; Medicated skincare preparations, namely, creams, lotions, gels, toners, cleaners and peels; Colostral antibodies for medical purposes; Medicated dermatological preparations and substances for skin renewal

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, February 10, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSTEMON Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressKR

Party NameSTEMON Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKR

Trademark Events


Event DateEvent Description
Friday, February 10, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 14, 2023APPLICATION FILING RECEIPT MAILED
Thursday, February 9, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Thursday, September 21, 2023ASSIGNED TO EXAMINER
Friday, September 22, 2023NON-FINAL ACTION WRITTEN
Wednesday, October 4, 2023REFUSAL PROCESSED BY MPU
Wednesday, October 25, 2023REFUSAL PROCESSED BY IB
Tuesday, March 19, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 19, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, September 23, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, October 4, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, March 19, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 28, 2024FINAL REFUSAL E-MAILED
Thursday, March 28, 2024FINAL REFUSAL WRITTEN
Thursday, March 28, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, April 24, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 24, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 8, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, April 24, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, April 25, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 28, 2024PUBLISHED FOR OPPOSITION
Tuesday, June 25, 2024EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, May 28, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED